| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/could-healthcare-stock-help-make-you-rich-over-next-decade","as_of":"2026-04-19T17:15:33.112665+00:00","canonical_url":"https://www.fool.com/investing/2026/04/19/could-this-healthcare-stock-help-make-you-rich/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/could-healthcare-stock-help-make-you-rich-over-next-decade","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_681d4ff2657d4aee","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/19/could-this-healthcare-stock-help-make-you-rich/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-19T18:42:38.004163+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsIntuitive Surgical continues to report double-digit revenue and earnings growth.","fetched_title":"Could This Healthcare Stock Help Make You Rich Over the Next Decade? | Nasdaq","final_url":"https://www.nasdaq.com/articles/could-healthcare-stock-help-make-you-rich-over-next-decade","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/could-healthcare-stock-help-make-you-rich-over-next-decade","source_event_id":"evt_22b91c4f0550","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"b76aa4c16c795e42","kind":"unusual_volume","published_at":"2026-04-19T16:05:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":["2025","2026","fourth quarter"],"entities":[{"asset_class":"equity","name":"Intuitive Surgical","relevance":"high","symbol":"ISRG","type":"company"},{"asset_class":"product","name":"da Vinci","relevance":"high","symbol":"","type":"product_platform"},{"asset_class":"equity","name":"Johnson & Johnson","relevance":"medium","symbol":"","type":"company"},{"asset_class":"equity","name":"Medtronic","relevance":"medium","symbol":"","type":"company"},{"asset_class":"equity","name":"Restore Robotics","relevance":"medium","symbol":"","type":"company"},{"asset_class":"regulation","name":"Food and Drug Administration (FDA)","relevance":"low","symbol":"","type":"regulator"}],"event_type":"other","information_gaps":["The provided signal type is discovery_unusual_volume_delta, but the text contains no explicit volume ratio, baseline volume, or direction of unusual volume.","No explicit statement confirms whether any volume spike is confirmed by news; the article discusses fundamentals and guidance rather than trading-volume data.","A specific catalyst hypothesis for unusual volume is not directly supported by the text; the closest catalyst discussed is da Vinci 5 rollout and 2026 guidance."],"key_facts":["Intuitive Surgical is described as the dominant manufacturer of robotic surgical systems.","The da Vinci platform is described as having performed more than 20 million surgical procedures (and more than 3 million procedures last year for da Vinci Xi).","The article states Intuitive has an installed base of more than 12,100 systems globally.","The article claims 81% of revenue comes from recurring sales of instruments, accessories, and services.","The article states 2025 revenue was $10.1 billion (+21%) and 2025 EPS was $7.87 (+22.5%).","The article states guidance for worldwide da Vinci procedures in 2026 is 13% to 15% and gross profit margin is 67% to 68% of revenue (vs 67.6% in 2025).","The article states da Vinci 5 rollout is a major catalyst for 2026 and cites force feedback technology that reduces the force applied by up to 43% (per Intuitive).","The article states that in the fourth quarter, 303 of 532 systems placed in medical settings were da Vinci 5 models.","The article notes the stock has fallen more than 17% so far this year and says shares have been down since its earnings release due to perceived underwhelming guidance."],"numeric_claims":[{"label":"2025 revenue","value":"$10.1 billion"},{"label":"2025 revenue growth","value":"21%"},{"label":"2025 EPS","value":"$7.87"},{"label":"2025 EPS growth","value":"22.5%"},{"label":"installed base systems","value":">12,100"},{"label":"recurring revenue share","value":"81%"},{"label":"procedure growth guidance (2026)","value":"13% to 15%"},{"label":"gross margin guidance (2026)","value":"67% to 68%"},{"label":"gross margin (2025)","value":"67.6%"},{"label":"da Vinci 5 force reduction","value":"up to 43%"},{"label":"Q4 systems placed","value":"532"},{"label":"Q4 da Vinci 5 systems placed","value":"303"},{"label":"stock decline so far this year","value":">17%"}],"primary_claim":"The da Vinci 5 rollout is presented as a major catalyst for 2026, with worldwide da Vinci procedure growth guidance of 13% to 15% and gross margin of 67% to 68% of revenue.","relevance_score":0.35,"sentiment":"mixed","source_quality":"high","summary":"The article argues Intuitive Surgical (NASDAQ: ISRG) remains positioned for strong long-term growth despite rising competition in robotic surgery. It highlights the da Vinci installed base, recurring revenue model, and the da Vinci 5 rollout as key drivers for 2026 procedure growth.","topics":["robotic surgery","installed base","recurring revenue","da Vinci 5 rollout","competition","financial guidance","research and development"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsIntuitive Surgical continues to report double-digit revenue and earnings growth.","tickers":[],"title":"Could This Healthcare Stock Help Make You Rich Over the Next Decade?","url":"https://www.fool.com/investing/2026/04/19/could-this-healthcare-stock-help-make-you-rich/"}... |